Although cervical cancer is an unusual cause of death among women 65 and older, most elderly women in the US report continuing to undergo periodic Pap smear screening. 
E
lderly women and their physicians face dif cult decisions regarding whether or not to continue screening for cervical cancer. While all guidelines strongly recommend regular Pap smear screening for young and middle-aged women, no such unanimity exists for the elderly. Many US professional societies, including the American College of Obstetrics and Gynecology, offer no upper age limit, while the American Cancer Society recently joined the United States Preventive Services Task Force in recommending that older women (over age 65 or 70) stop screening if they have had previously normal exams. [1] [2] [3] [4] Outside the United States, screening women over 70 is extremely rare. 5 These disparities re ect widespread uncertainty about the bene ts of screening the elderly for cervical cancer. Most authorities do agree that any bene ts, if they exist, are likely to be quite small. 1, 6 The decision to continue screening, therefore, should depend on how women weigh a small and uncertain bene t against the downsides of screening. Easily recognizable downsides of Pap smear screening include patient inconvenience and discomfort, 7, 8 both likely to increase with age. The likelihood that an abnormal Pap smear will require further evaluation should also be considered. It is estimated that as many as 5% of Pap smears are read as abnormal, and are thus likely to lead to follow-up testing . 9 Scant data are available, however, on the downstream consequences of Pap smear testing among elderly women. In fact, we were surprised to nd that there are almost no population-based data on rates of intervention following Pap smear testing for women of any age.
Despite uncertain bene ts and lack of accurate information on the downsides of screening, Pap smear testing is common among elderly women. Survey data from 1998 suggest that almost two thirds of women over 65 are undergoing screening, 10 and the numbers of older women being screened continue to increase. 11 Thus, quanti cation of the downsides of Pap smear screening in the elderly has become increasingly important. Using Medicare outpatient claims data les, 12 we sought to describe the downstream Pap smear screening experience among American women over age 65.
METHODS

Data
We used data from a 5% sample of the Part B Physician Supplier le of Medicare's National Claims History System (a publicly available database of all claims for 5% of Medicare enrollees, released annually by the Health Care Financing Administration, Baltimore, MD) to identify women who had undergone Pap smear testing during the three year period 1995-1997. In order to ensure complete availability of claims data for each woman, we excluded those who were ineligible for Medicare Part B (outpatient coverage), and those who enrolled in risk-contract managed care plans (HMO's).
Pap smear incidence
We estimated the proportion of elderly Medicare bene ciaries undergoing screening as follows. For the numerator, we used the number of women over 65 with any Pap smear interpretation procedure code during the three-year period 1 January 1995-31 December 1997. (See Appendices A-C for procedure [CPT] and diagnosis codes used in the study.) We used a three year window because Pap smear screening every three years is endorsed by most US organizations and reimbursed under Medicare. We did not exclude Pap smears with an 'allowed charge'=US$0.00, because of Medicare's narrow de nition of a reimbursable Pap smear. (Restrictions limiting women to one screening Pap smear every three years, and requiring a diagnosis suggestive of genital abnormality for smears coded as non-screening). Because of this, approximately 25% of women with Pap smear codes had no CPT code with an 'allowed charge' >US$0.00. For the denominator, we used the number of females who were Part B eligible, non-HMO enrolled Medicare bene ciaries over age 65 at the midpoint of the three year period (1 July 1996) .
Because Pap smears are poorly reimbursed under Medicare (~US$6 per test), we hypothesized substantial underbilling. In order to estimate the extent of underbilling, we analyzed prior claims on approximately 2000 women who underwent colposcopy in 1996, each of whom had almost certainly had a Pap smear during the preceding year. Only 59% had one or more Pap smear claims (or a previous colposcopy) during the 12 months prior to colposcopy, suggesting that approximately 41% of Medicare eligible women who have a Pap smear do not have an associated claim.
The downstream events study population
Our primary investigation focuses on downstream events during the eight months following a Pap smear. We therefore required that claims data was available for each woman for the full eight months following her Pap smear. We chose an eight month follow-up period presuming it would encompass most evaluations of abnormal Pap smears, while excluding a woman's next annual Pap smear. In order to determine the indication for each Pap smear, claims also had to be available for the full 12 months preceding a woman's Pap smear, which required that women were at least 66 years old on the day of the Pap smear (assuring one year of prior Medicare eligibility). The study population was therefore restricted to women 66 years and older with a Pap smear between 1 January 1996 and 30 April 1997, who had no gaps in Part B coverage during the 12 months prior to and eight months following the Pap smear.
We excluded women whose Pap smear may have been performed for symptoms rather than for screening. We therefore eliminated women with a diagnostic code (e.g. metrorhaggia) or a procedure code (e.g. endometrial biopsy) suggestive of post-menopausal vaginal bleeding during the three months prior to the Pap smear. (See Appendices A and B for listing of CPT and ICD-9 codes used to identify bleeding.) For each woman remaining (n=121,902), we de ned the rst Pap smear between 1 January 1996 and 30 April 1997 as the index Pap smear.
Determining Pap smear indication
Women undergoing Pap smear testing for surveillance of previous abnormalities or to follow up a prior abnormal Pap are likely to undergo downstream testing at higher rates than women undergoing screening Pap smears. We therefore used claims activity from the 12 months prior to the index Pap smear in order to divide the study population into three mutually exclusive cohorts based on Pap smear indication, as shown in Figure 1 . The surveillance cohort included women whose Pap smear was likely to have been performed in surveillance of past cervical neoplasiawomen who had a diagnosis (e.g. malignant neoplasm corpus uteri) or a procedure (e.g. cone biopsy) associated with a gynecologic neoplasm during the previous year. Of the remaining women, those who had a Pap smear code during the nine months prior to the index Pap smear constituted the Pap follow-up cohort. Women who did not meet the criteria for the Surveillance or Pap follow-up cohorts were assigned to the Screening cohort.
Downstream events
For each woman, we recorded all CPT codes for Pap smears, colposcopies and surgical procedures performed within 240 days following the index Pap smear. (See Appendix A for CPT codes.) For all downstream procedures we report only whether a woman had any code for each separate procedure (e.g. colposcopy), and not whether a woman had undergone more than one. Counting follow-up procedures
In the case in which multiple Pap smear codes were present for one woman within several days of each other, we presumed that double-counting, double-billing or repeat billing for Pap smears not reimbursed may have taken place. In order to determine the window outside of which a second Pap smear code would be counted as a separate Pap smear, we evaluated a random sample of 200 sets of two or more Pap smear codes on one woman during a 180 day period. Based on information including Pap smear-associated ICD-9 codes, allowable charges, and providers, we found that Pap smear codes more than ve days following another Pap smear CPT code were likely to represent separate Pap smear procedures. Of subsequent Pap smear codes within six months of a rst Pap smear, 24% occurred within ve days of the rst smear and were presumed to be repeat bills for a single procedure rather than second Pap smears. Fewer than 5% of all second smears occurred between six and 15 days following the rst smear. Thus, we recorded follow-up Pap smears starting at six days after the index smear, and required at least six days between subsequent smears in order to count as two separate downstream events.
Hysterectomy
We also recorded all procedure codes for hysterectomy among women in the three cohorts. Because the majority of hysterectomies are likely to be performed because of a gynecological condition unrelated to results of the Pap smear, we did not classify hysterectomies as downstream events. However, because women unconcerned with preserving fertility may be offered hysterectomy as an alternative to lesser surgical procedures (e.g. conisation) or frequent Pap follow-up, it is likely that some fraction of hysterectomies among elderly women who undergo Pap smear testing are actually a downstream consequence of abnormal Pap smears. We used diagnostic codes associated with each hysterectomy and the antecedent Pap smear to determine whether the procedure was likely a downstream consequence of the Pap smear, and thereby estimated the rate of downstream hysterectomies. (Appendix C describes the generation of low-and high-bound estimates). Codes 88151 and 88157 indicate physician interpretation, rather than cytotechnologist interpretation; however not every physician interpretation code is preceded by a cytotechnologist code -therefore codes 88151 and 88157 were considered the same as the other codes with one exception: a 88151 or 88157 code appearing within 30 days following another Pap smear code was NOT counted as a separate and distinct Pap smear.
Analysis
We calculated the adjusted three-year Pap smear incidence by dividing the crude incidence by the estimated proportion of Pap smears actually billed (59%). We report rates of downstream testing as the number of downstream procedures per 1000 women undergoing Pap smear testing.
Appendix A Current procedural terminology (CPT) codes used to identify the following procedures mentioned in the text. We calculated 95% con dence intervals (CI) using the exact binomial CI function for proportions in STATA Software (version 6.0, Stata Corporation, College Station, TX, 1999).
RESULTS
Pap smear incidence
Approximately four million female Medicare bene ciaries over 65 years old had at least one Medicare claim for a Pap smear during the three year period 1995-1997, representing 25% of the age-speci c female population (See Table 1 ). Thirty three percent of women aged 66-75 years had Pap smear claims, as did 20% of those aged 76-85 years, and 9% of women aged 86-100 years. When adjusted for underbilling, an estimated 43% of elderly women had at least one Pap smear during the three year period 1995-1997 (for women aged 66-75 years, 76-85 years, and 86-100 years, the proportions were 55%, 34%, and 14%, respectively).
Downstream events
Between 1 January 1996 and 30 April 1997, 121,902 women (in the Medicare 5% sample) had at least one Pap smear and were included in the 'downstream events' study population. Of these, 9763 (8%) women had undergone a procedure or had a diagnosis suggestive of gynecological neoplasia within the 12 months prior to the Pap smear and were assigned to the surveillance cohort. An additional 1841(2%) had undergone a Pap smear within the nine month period prior to the index Pap smear, and were included in the Pap follow-up cohort. The screening cohort consists of the remaining 110,298 women (90%). Table 2 shows the rates of downstream testing among the three cohorts. Among women in the screening cohort, 39 per 1000 underwent at least one form of downstream testing during the eight months following the initial Pap smear -35 had one or more follow-up Pap smears, seven underwent colposcopy, and two had a more invasive surgical procedure. Rates of downstream intervention were considerably higher for women in the other two (non-screening) cohorts. Among women in the Pap follow-up cohort, 302 per 1000 had at least one downstream intervention, including 288 with a subsequent Pap smear, 19 who underwent colposcopy, and six who had a surgical procedure. Among women in the surveillance cohort, 209 women per 1000 had one or more downstream interventions, including 171 with a subsequent Pap smear, 56 who underwent colposcopy and 16 who had a surgical procedure. Rates of subsequent Pap smears are likely to be considerably higher than these gures suggest (after adjusting for underbilling for Pap smears).
Downstream events according to age
There were modest differences in rates of downstream testing according to age. Figure 2 displays, for the screening cohort only, the likelihood of downstream testing for each Appendix C Classi cation of hysterectomies as downstream events.
We used both narrow and broad criteria to attribute a hysterectomy to an antecedent Pap smear. This process generated a low-and high-bound estimate, respectively, of the rate of downstream hysterectomies after Pap smears. For both criteria, we rst excluded all women for whom diagnostic codes (ICD-9 codes) associated with the hysterectomy speci ed neoplasm other than the cervix. This was done to avoid counting a hysterectomy done for uterine, ovarian, colon, or other malignancy as a downstream event following a Pap smear. Our narrow criterion for a downstream hysterectomy required that the primary diagnostic code associated with the hysterectomy identi ed a cervical abnormality*. Our broad criterion included any one of the following a) a hysterectomy that met our narrow criterion, b) a hysterectomy for which the secondary diagnostic code was a cervical abnormality, or c) a hysterectomy for which the antecedent Pap smear was done because of a cervical abnormality (as the primary diagnostic code). 
Hysterectomy
Among women in the screening cohort, 8.5 per 1000 screened underwent hysterectomy during the eight months following the index Pap smear. Rates of hysterectomy were higher among women in the surveillance (25.5 per 1000) and Pap follow-up cohorts (19.6 per 1000). Hysterectomy rates were similar for women aged 66-75 and 76-85 years, and fell modestly among women age 86 and older. Based on the hysterectomy indication attached to the procedure claim, we estimated that between 4% and 5% of hysterectomies among the screening cohort were direct (downstream) consequences of Pap smear testing. This was true for between 13% and 32% of hysterectomies in the surveillance cohort and for no hysterectomies among women in the Pap follow-up cohort.
DISCUSSION
We found that Pap smear screening is common among elderly female Medicare bene ciaries: an estimated 43% of women over age 65 were screened during a three year period. Rates of subsequent testing among women undergoing Pap smear screening are not negligible -nearly 40 women per 1000 underwent further testing within eight months of the Pap smear -and were many times higher among women undergoing Pap smears for surveillance or Pap follow-up. Finally, rates of downstream interventions remained high even among the oldest women, although rates of invasive procedures declined modestly among those over age 85. Our study has several limitations. Firstly, claims-based analysis is only as accurate as the claims themselves. It appears likely that, because of low reimbursement, Pap smear claims may substantially underestimate the frequency of Pap smear testing -only 59% of women had a Pap smear claim during the 12 months prior to colposcopy. We therefore report not only the proportion with a Pap smear claim, but also an adjusted estimate of the proportion that underwent testing, accounting for underbilling. (In the unlikely event that a signi cant number of women undergo colposcopy without having rst had a Pap smear, our adjusted estimate of Pap smear incidence would be exaggerated.) Although we may have similarly understated rates of downstream Pap smears, it is less likely that we have substantially underestimated rates of more generously reimbursed downstream procedures such as colposcopy and cryosurgery, as prior work has demonstrated reasonable sensitivity and speci city of Medicare claims data, especially for procedures. [13] [14] [15] Secondly, our reliance on claims data required us to infer the indication for each Pap smear. The distinctly different pattern of downstream events for each of the three cohorts, however, provides reasonable face validity. If our assumptions introduce any systematic bias, it would be that because of underbilling for previous Pap smears, the screening cohort may include a very small number of women (1% of the cohort) actually undergoing Pap follow-up. Lastly, we also had to infer the causal connection between a Pap smear and the procedures we considered 'downstream' from that Pap smear. While causality cannot be de nitively established without reviewing medical records, all procedures (except subsequent Pap smears) included as downstream events are rarely if ever performed in the absence of an antecedent abnormal Pap smear. The exception would be hysterectomy, which we have not categorized as a downstream consequence of screening, although our analysis of diagnostic codes suggests that this does occur.
Our results expand upon prior work examining Pap smear screening prevalence and consequences among elderly women. Our nding that 43% of elderly American women are screened during a three year period is substantially lower than previous estimates of between 64% and 87%. [16] [17] [18] [19] Several factors help to explain the discrepancy between our results and these survey-based estimates. In contrast to Medicare data, survey data exclude women who are institutionalized, who have a low likelihood of screening, but include women enrolled in Medicare managed care plans, who are likely to be screened at higher rates than the general elderly population. In addition, self-reports of Pap smear history consistently overestimate actual screening. [20] [21] [22] [23] [24] [25] We suspect that the true proportion of elderly women screened lies somewhere between the survey-and claims-based estimates -i.e. between 43% and 64% of women over 65 are screened during any given three year period.
While little previous work has examined rates of downstream consequences of Pap smear testing, our estimates are consistent with what is known of the outcomes of screening. Overall, an estimated 2-3%, or 20-30 per 1000 Pap smears are abnormal among women over age 60. 26 In small studies in the USA [27] [28] [29] and Great Britain, 30 similar proportions of elderly women -between 20 and 60 per 1000 -required further evaluation after a Pap smear. In the only previous population-based study of downstream interventions, 7.6 per 1000 Australian women age 65 and older undergoing a Pap smear required colposcopy 31 -nearly identical to the proportion undergoing colposcopy among our Medicare Screening cohort. Similar population-based estimates are lacking for women undergoing surveillance of previous abnormalities, whose rates of downstream interventions we found to be substantially higher.
While recommendations supporting Pap smear screening are based on strong evidence from observational studies, these studies included few women over 65. 32, 33 Although cervical cancer mortality climbs after age 65, any bene t of screening is expected to decline markedly with age due to increases in competing causes of death and long delays in the realization of bene ts of screening. Because the bene ts of cervical cancer screening in the elderly are so uncertain, a realistic assessment of the potential harms is essential. Some of the downsides are obvious (discomfort and inconvenience) and apply to all screened women, but are dif cult to measure. Others, however, can be measured. In addition to our quanti cation of the burden of downstream testing in the elderly, several small Pap smear outreach studies highlight the potential pitfalls of screening this population. Rates of refusal of follow-up were high, and not uncommonly, some participants went to hysterectomy only to nd no malignancy detected, while others died of unrelated causes while undergoing evaluation. [27] [28] [29] Medicare has provided reimbursement for Pap smear screening only since 1990, largely motivated by ndings that up to 40% of elderly women in the United States had never had a Pap smear. [34] [35] [36] [37] Women never screened, who have the highest incidence of and mortality from cervical cancer and the lowest likelihood of future screening 38 , bene t the most from screening. 6, 32, 39 It is at these women that public health campaigns to lower cervical cancer incidence and mortality are aimed. 40 Little effort, however, has been made to ensure that women screened through Medicare are those who have never been previously screened, rather than those with a lifetime of previous normal Pap smears.
Our results show that Pap smear screening among the elderly, while by no means universal, is common. Other work has shown that rates of reported Pap smear screening are on the rise. 11 While many US professional societies have begun to recommend against screening elderly women -as has long been the practice in other industrialized nationsthe drive toward increased screening as a component of quality improvement initiatives has largely been age-blind. It is not clear whether, at a time of increasing Medicare cost constraints, the promotion of higher rates of cervical cancer screening represents the best use of resources nor whether continuing screening represents a well-informed choice for individual women. Certainly, promotion of screening in elderly women who have never been screened should remain an important goal. However, decisions regarding the continuation of screening in elderly women with a lifetime of normal Pap smears should acknowledge the low risk of development of cancer, the declining bene ts of screening with increasing age, and the modest probability that Pap smear screening does not end after the Pap smear.
